Hansa Biopharma Completes Randomization in Pivotal Phase 3 US ConfIdeS Trial ...Middle East

LUND, Sweden, May 31, 2024 /PRNewswire/ -- Hansa Biopharma AB, ("Hansa" or the "Company") (NASDAQ Stockholm: HNSA), today announced recruitment and randomization in its US ConfIdeS trial is complete. ConfIdeS is a pivotal Phase 3 open label, randomized, controlled trial of imlifidase in...

Hence then, the article about hansa biopharma completes randomization in pivotal phase 3 us confides trial was published today ( Friday 31/05/2024 - 03:29 PM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Hansa Biopharma Completes Randomization in Pivotal Phase 3 US ConfIdeS Trial )

Also on site :

• Gold Star Distribution Inc., Issues Recall of Certain FDA-Regulated Products in Three States Including Drugs, Devices, Cosmetics, Human Foods, and Pet Foods
• ’Beverly Hills, 90210’s Jason Priestley Shares Bold Callout After ‘Worst’ Travel Experience
• Central African Republic election: Who’s running and what’s at stake?